[go: up one dir, main page]

DE69715631D1 - Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit - Google Patents

Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit

Info

Publication number
DE69715631D1
DE69715631D1 DE69715631T DE69715631T DE69715631D1 DE 69715631 D1 DE69715631 D1 DE 69715631D1 DE 69715631 T DE69715631 T DE 69715631T DE 69715631 T DE69715631 T DE 69715631T DE 69715631 D1 DE69715631 D1 DE 69715631D1
Authority
DE
Germany
Prior art keywords
convulsive
obesity
treatment
sulfamate derivatives
sulfamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69715631T
Other languages
English (en)
Other versions
DE69715631T2 (de
Inventor
P Shank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69715631(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE69715631D1 publication Critical patent/DE69715631D1/de
Publication of DE69715631T2 publication Critical patent/DE69715631T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69715631T 1996-06-28 1997-06-23 Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit Expired - Lifetime DE69715631T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2200496P 1996-06-28 1996-06-28
PCT/US1997/010953 WO1998000130A2 (en) 1996-06-28 1997-06-23 Anticonvulsant sulfamate derivatives useful in treating obesity

Publications (2)

Publication Number Publication Date
DE69715631D1 true DE69715631D1 (de) 2002-10-24
DE69715631T2 DE69715631T2 (de) 2003-05-08

Family

ID=21807338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69715631T Expired - Lifetime DE69715631T2 (de) 1996-06-28 1997-06-23 Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit

Country Status (24)

Country Link
US (1) US6071537A (de)
EP (1) EP0915697B1 (de)
JP (1) JP2000514425A (de)
CN (1) CN1106193C (de)
AP (1) AP1285A (de)
AT (1) ATE224189T1 (de)
AU (1) AU732923B2 (de)
BR (1) BR9710994A (de)
CA (1) CA2258893C (de)
CZ (1) CZ293876B6 (de)
DE (1) DE69715631T2 (de)
DK (1) DK0915697T3 (de)
ES (1) ES2184127T3 (de)
HK (1) HK1018743A1 (de)
HU (1) HU226775B1 (de)
IL (1) IL127715A (de)
NO (1) NO317754B1 (de)
NZ (1) NZ333586A (de)
PT (1) PT915697E (de)
RU (1) RU2214241C2 (de)
SK (1) SK284305B6 (de)
UA (1) UA53655C2 (de)
WO (1) WO1998000130A2 (de)
ZA (1) ZA975772B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
MXPA01010223A (es) * 1999-04-08 2002-09-18 Johnson & Johnson Derivados anticonvulsivos utiles para mantener la perdida de peso.
NZ514812A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering blood pressure
CA2369093C (en) * 1999-04-08 2005-10-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
JP4709392B2 (ja) * 1999-04-08 2011-06-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
PL365680A1 (en) * 2000-07-07 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
EP1333887B1 (de) * 2000-10-30 2006-08-02 Ortho-McNeil Pharmaceutical, Inc. Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
CA2430010A1 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AU2005244151A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA010977B1 (ru) * 2004-08-24 2008-12-30 Янссен Фармацевтика Н.В. Бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
CN101754947A (zh) * 2005-05-20 2010-06-23 詹森药业有限公司 磺酰胺衍生物的制备方法
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
EP2026790A2 (de) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
RS60682B1 (sr) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4586916A (en) * 1985-01-30 1986-05-06 Consolidated Papers, Inc. Corrugated carton separator
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates

Also Published As

Publication number Publication date
SK180598A3 (en) 2000-07-11
EP0915697A2 (de) 1999-05-19
RU2214241C2 (ru) 2003-10-20
NO317754B1 (no) 2004-12-13
CN1224352A (zh) 1999-07-28
DE69715631T2 (de) 2003-05-08
CN1106193C (zh) 2003-04-23
NO986052D0 (no) 1998-12-22
CZ427898A3 (cs) 1999-08-11
HU226775B1 (en) 2009-09-28
CZ293876B6 (cs) 2004-08-18
HUP0001192A3 (en) 2002-09-30
AU732923B2 (en) 2001-05-03
US6071537A (en) 2000-06-06
WO1998000130A2 (en) 1998-01-08
HK1018743A1 (en) 2000-01-07
UA53655C2 (uk) 2003-02-17
NO986052L (no) 1999-02-23
SK284305B6 (sk) 2005-01-03
ZA975772B (en) 1998-12-28
BR9710994A (pt) 2000-10-24
WO1998000130A3 (en) 1998-02-12
JP2000514425A (ja) 2000-10-31
ES2184127T3 (es) 2003-04-01
NZ333586A (en) 2000-05-26
IL127715A (en) 2004-07-25
HUP0001192A2 (hu) 2000-11-28
AP9801429A0 (en) 1998-12-31
PT915697E (pt) 2003-02-28
EP0915697B1 (de) 2002-09-18
AU3957897A (en) 1998-01-21
IL127715A0 (en) 1999-10-28
ATE224189T1 (de) 2002-10-15
CA2258893C (en) 2005-06-14
DK0915697T3 (da) 2003-01-27
CA2258893A1 (en) 1998-01-08
AP1285A (en) 2004-06-24

Similar Documents

Publication Publication Date Title
DE69715631D1 (de) Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
ATE235236T1 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69528109D1 (de) Thieno -1,5- benzodiazepin zur Behandlung gastrointestinaler Beschwerden
DE69500089D1 (de) Behandlung von Geflügel
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE301617T1 (de) Behandlung von wasser
DE69806579D1 (de) Anlage zur behandlung von nahrungsmitteln
ATE349216T1 (de) Behandlung von darmverstopfung
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
IS5056A (is) Ný meðhöndlun á liðbólgu
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69716453D1 (de) Antikonvulsive derivate zur behandlung von neuropathischem schmerz
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69828998D1 (de) Indolderivate verwendbar zur behandlung von u.a. osteoporosis
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN